产品说明书
Tenoxicam
 |
同义名 : | Ro-12-0068 |
| CAS号 : | 59804-37-4 | |
| 货号 : | A230274 | |
| 分子式 : | C13H11N3O4S2 | |
| 纯度 : | 98% | |
| 分子量 : | 337.374 | |
| MDL号 : | MFCD00083502 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 50 mg/mL(148.2 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
IP 2% DMSO+2% Tween80+30% PEG300+water 1.1 mg/mL clear PO 0.5% CMC-Na 35 mg/mL suspension |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Tenoxicam is an oxicam preferentially cyclooxygenase-1 (COX-1) inhibitor. Tenoxicam may have antioxidant effects, and that celecoxib and tenoxicam may reduce nitrite levels, indicating an alteration of NO (nitric oxide) pathways[3]. Tenoxicam was administered intraperitoneally immediately after BCAO( both common carotid arteries). Histological analyses show that ischemia produced significant striatal as well as hippocampal lesions which were reversed by the Tenoxicam treatment. Tenoxicam also significantly reduced, to control levels, the increased myeloperoxidase activity in hippocampus homogenates observed after ischemia[4]. Additionally, apart from oral use, tenoxicam is also applied as an intra-articular treatment option to minimize gastrointestinal side effects of NSAIDs[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT01638962 | Osteoarthritis, Knee | Not Applicable | Completed | - | Denmark ... 展开 >> University of Southern Denmark Odense, Region Syddanmark, Denmark, 5230 收起 << |
| NCT00635986 | Fentanyl Analgesia | Not Applicable | Completed | - | - |
| NCT01652183 | Catheter Related Bladder Disco... 展开 >>mfort 收起 << | Phase 4 | Completed | - | Turkey ... 展开 >> Baskent University School of Medicine Adana Teaching and Research Hospital Adana, Turkey, 01250 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.96mL 0.59mL 0.30mL |
14.82mL 2.96mL 1.48mL |
29.64mL 5.93mL 2.96mL |
| 参考文献 |
|---|